
SK bioscience Co.,Ltd.
KRX:302440.KS
48400 (KRW) • At close July 1, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|---|---|
Operating Activities: | |||||||
Net Income
| -50,117.07 | 22,317.718 | 122,451.95 | 355,139.277 | 32,889.712 | 14,677.405 | 420.845 |
Depreciation & Amortization
| 49,225.234 | 34,764.703 | 27,236.409 | 18,775.305 | 16,527.436 | 14,543.238 | 6,594.926 |
Deferred Income Tax
| 0 | 0 | 0 | 0 | -719.864 | -5,587.062 | 4,327.733 |
Stock Based Compensation
| 0 | 0 | 0 | 0 | 575.454 | 300.237 | 25.02 |
Change In Working Capital
| 40,062.918 | -18,391.696 | -208,378.665 | 44,000.929 | 66,407.706 | 8,061.487 | 1,114.223 |
Accounts Receivables
| -2,471.949 | 26,673.86 | -44,647.416 | -398.647 | -14,609.697 | 12,254.972 | -12,664.522 |
Inventory
| 79,409.985 | 52,888.273 | -96,229.843 | -70,337.103 | -31,573.385 | -6,887.871 | 6,876.125 |
Accounts Payables
| 0 | 0 | -52,758.718 | 46,536.207 | -866.886 | 7,295.049 | -7,029.846 |
Other Working Capital
| -36,875.118 | -97,953.829 | -14,742.688 | 68,200.472 | 113,457.674 | -4,600.663 | -5,761.902 |
Other Non Cash Items
| -167,190.951 | -9,344.364 | -66,267.978 | 118,678.177 | 4,543.347 | 3,977.22 | 2,419.772 |
Operating Cash Flow
| -128,019.869 | 29,346.361 | -124,958.284 | 536,593.688 | 120,223.791 | 35,972.525 | 14,902.519 |
Investing Activities: | |||||||
Investments In Property Plant And Equipment
| -164,413.439 | -50,295.489 | -76,489.443 | -44,469.56 | -10,197.57 | -23,968.408 | -6,309.972 |
Acquisitions Net
| -216,757.524 | 0 | 34.566 | 5,819.51 | 197.839 | 99.922 | 0 |
Purchases Of Investments
| -9,490.066 | -111,396.35 | -1,000.087 | -1,385,607.013 | -102,396.742 | -99.922 | -11,323.366 |
Sales Maturities Of Investments
| 432,819.164 | 118,773.445 | 353,052.205 | 990 | 3,262.04 | 21,019.983 | 0 |
Other Investing Activites
| 11,405.668 | -2,360.327 | -2,950.736 | 1,326.778 | 1,041.516 | 302.465 | -9.16 |
Investing Cash Flow
| 53,563.803 | -45,278.721 | 272,646.505 | -1,421,940.285 | -108,092.918 | -2,645.959 | -17,642.498 |
Financing Activities: | |||||||
Debt Repayment
| 192,056.904 | -83,553.994 | -55,031.22 | -22,410.369 | -1,237.367 | -23,435.486 | -10,000 |
Common Stock Issued
| 75,680.234 | 397.599 | 2,617.946 | 983,255.829 | -301.455 | 0 | 10,981.864 |
Common Stock Repurchased
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Dividends Paid
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing Activities
| -15,257.91 | -6,426.221 | 32,546.113 | -2,465.174 | 0 | 0 | -144 |
Financing Cash Flow
| 252,479.228 | -89,582.616 | -19,867.162 | 958,380.287 | -1,538.822 | -23,435.486 | 837.864 |
Other Information: | |||||||
Effect Of Forex Changes On Cash
| 7,652.705 | 7,253.167 | -561.871 | 22.252 | 0 | 0 | -0 |
Net Change In Cash
| 185,675.868 | -98,261.81 | 127,259.187 | 73,055.941 | 10,592.051 | 9,891.079 | -1,902.116 |
Cash At End Of Period
| 312,701.506 | 127,025.639 | 225,287.448 | 98,028.261 | 24,972.321 | 14,380.269 | 4,489.19 |